loading page

Anastrozole as a therapeutic option for gynecomastia in a person receiving antiretroviral treatment: case report
  • +2
  • Elizabeth Senkoro,
  • Maithili Varadarajan,
  • Caterina Candela,
  • Christina Antoniad,
  • Marta Boffito
Elizabeth Senkoro
Chelsea and Westminster Hospital
Author Profile
Maithili Varadarajan
Chelsea and Westminster Hospital
Author Profile
Caterina Candela
Chelsea and Westminster Hospital
Author Profile
Christina Antoniad
Chelsea and Westminster Hospital
Author Profile
Marta Boffito
Chelsea and Westminster Hospital

Corresponding Author:marta.boffito@nhs.net

Author Profile

Abstract

A middle-aged Caucasian man presented with a six-month history of bilateral enlargement of the breasts associated with pain. His hormonal profile was normal and no other underlying cause was identified, we diagnosed him with idiopathic gynecomastia. He is living with HIV, clinically stable (viral load <20copies/mL) and on injectable antiretrovirals cabotegravir/rilpivirine. Tamoxifen is an anti-estrogen recommended for gynecomastia and has been described in persons living with HIV. In this case, tamoxifen could potentially induce the activity of cytochrome P450 3A4 (CYP3A4), reducing rilpivirine concentrations, which consequently may cause virological failure. According to the National Health Service (NHS) guidelines in the UK, an aromatase inhibitor can be used in place of tamoxifen. To date, there have been no reported cases of using anastrozole as a treatment for gynecomastia in people living with HIV, or of its co-administration with antiretrovirals.
25 Aug 2023Submitted to British Journal of Clinical Pharmacology
27 Aug 2023Submission Checks Completed
27 Aug 2023Assigned to Editor
27 Aug 2023Review(s) Completed, Editorial Evaluation Pending
06 Sep 2023Reviewer(s) Assigned
03 Oct 2023Editorial Decision: Revise Major
23 Oct 20231st Revision Received
24 Oct 2023Submission Checks Completed
24 Oct 2023Assigned to Editor
24 Oct 2023Review(s) Completed, Editorial Evaluation Pending
25 Oct 2023Editorial Decision: Accept